Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$15.45M |
$1.04
-7.96%
|
|
KAPA
Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharma focused on oncology therapies, including immunotherapies and cell therapies.
|
$15.35M |
$0.74
+1.39%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$15.00M |
$0.29
-7.98%
|
|
NXGL
NEXGEL, Inc.
NXGEL generates revenue from contract manufacturing of hydrogel-based medical and consumer products.
|
$14.68M |
$1.84
+2.50%
|
|
OSRH
OSR Holdings, Inc.
VAXIMM's lead oncology immunotherapy candidate positions OSRH in the Biotech - Oncology space.
|
$14.66M |
$0.68
-17.27%
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$14.41M |
$1.41
+15.16%
|
|
TPST
Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
|
$14.25M |
$3.20
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$13.82M |
$0.41
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$13.68M |
$0.07
|
|
ACUT
Accustem Sciences Inc.
Tests and technologies are oncology-focused biomarker diagnostics, placing ACUT in the oncology diagnostics space.
|
$13.27M |
$0.88
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
Sonnet's core pipeline is oncology-focused immunotherapies (e.g., SON-1010 IL-12) leveraging the FHAB platform.
|
$13.15M |
$4.16
-0.12%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
Lead candidate Phyto-N targets inflammatory diseases, placing CURX in the Biotech - Immunology Therapeutics space.
|
$13.15M |
$0.47
+0.41%
|
|
PCSA
Processa Pharmaceuticals, Inc.
Processa is a oncology-focused biotech developing Next Generation Cancer therapies (NGCs), placing it squarely in Biotech - Oncology.
|
$12.66M |
$0.25
+5.12%
|
|
ALUR
Allurion Technologies Inc.
Drug delivery platform angle via GLP-1 drug-eluting intragastric balloon; joint development.
|
$12.50M |
$1.62
+12.50%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$12.01M |
$1.72
+2.38%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$11.87M |
$2.58
+2.79%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$11.40M |
$0.27
+2.28%
|
|
MGRX
Mangoceuticals, Inc.
Patented antiviral small-molecule therapeutics (MGX-0024) introduced as an IP asset with clinical development.
|
$11.27M |
$1.08
-1.82%
|
|
CLRB
Cellectar Biosciences, Inc.
Core product category: radiopharmaceuticals developed and marketed by Cellectar as radioconjugate therapies.
|
$11.01M |
$3.42
+11.56%
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$10.92M |
$1.45
+7.41%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Sensei's lead asset targets oncology/cancer indications, fitting the Biotech - Oncology category.
|
$10.66M |
$8.75
+1.74%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$10.59M |
$1.37
+1.48%
|
|
COCP
Cocrystal Pharma, Inc.
Cocrystal Pharma is actively developing antiviral small-molecule therapeutics (CC-42344, CDI-988, CC-31244) for influenza, norovirus/coronavirus, and HCV.
|
$10.36M |
$1.02
+8.31%
|
|
PPCB
Propanc Biopharma, Inc.
Propanc Biopharma is a development-stage biotechnology company focusing on oncology therapies, making PRP its core candidate.
|
$10.31M |
$0.82
-0.35%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$10.14M |
$0.40
+6.35%
|
|
MDXH
MDxHealth S.A.
GPS test provides biomarker-based risk stratification that informs treatment decisions, aligning with Companion Diagnostics.
|
$10.01M |
$3.65
+1.96%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$10.00M |
$1.05
-3.21%
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
|
$9.98M |
$1.02
+0.99%
|
|
IMRN
Immuron Limited
Core polyclonal antibody technology platform powering gut-health products and clinical programs in immunology/biotherapeutics.
|
$9.97M |
$1.76
+1.44%
|
|
LGVN
Longeveron Inc.
LGVN's lead candidate laromestrocel is a mesenchymal stem cell (MSC) therapy, directly aligning with Biotech - Cell Therapy.
|
$9.83M |
$0.65
+7.77%
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$9.83M |
$2.17
+3.10%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$9.58M |
$0.38
+0.18%
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$9.55M |
$0.59
-1.05%
|
|
BOLT
Bolt Biotherapeutics, Inc.
The company develops monoclonal antibody therapeutics (e.g., BDC-3042) as part of its ISAC platform.
|
$9.50M |
$5.08
+0.30%
|
Showing page 22 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
